Hirasawa A - Search Results

1

MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma.

Kang EY, Millstein J, Popovic G, Meagher NS, Bolithon A, Talhouk A, Chiu DS, Anglesio MS, Leung B, Tang K, Lambie N, Pavanello M, Da-Anoy A, Lambrechts D, Loverix L, Olbrecht S, Bisinotto C, Garcia-Donas J, Ruiz-Llorente S, Yagüe-Fernandez M, Edwards RP, Elishaev E, Olawaiye A, Taylor S, Ataseven B, du Bois A, Harter P, Lester J, Høgdall CK, Armasu SM, Huang Y, Vierkant RA, Wang C, Winham SJ, Heublein S, Kommoss FKF, Cramer DW, Sasamoto N, van-Wagensveld L, Lycke M, Mateoiu C, Joseph J, Pike MC, Odunsi K, Tseng CC, Pearce CL, Bilic S, Conrads TP, Hartmann A, Hein A, Jones ME, Leung Y, Beckmann MW, Ruebner M, Schoemaker MJ, Terry KL, El-Bahrawy MA, Coulson P, Etter JL, LaVigne-Mager K, Andress J, Grube M, Fischer A, Neudeck N, Robertson G, Farrell R, Barlow E, Quinn C, Hettiaratchi A, Casablanca Y, Erber R, Stewart CJR, Tan A, Yu Y, Boros J, Brand AH, Harnett PR, Kennedy CJ, Nevins N, Morgan T, Fasching PA, Vergote I, Swerdlow AJ, Candido Dos Reis FJ, Maxwell GL, Neuhausen SL, Barquin-Garcia A, Modugno F, Moysich KB, Crowe PJ, Hirasawa A, Heitz F, Karlan BY, Goode EL, Sinn P, Horlings HM, Høgdall E, Sundfeldt K, Kommoss S, Staebler A, Wu AH, Cohen PA, DeFazio A, Lee CH, Stee… See abstract for full author list ➔ Kang EY, et al. Among authors: hirasawa a. Virchows Arch. 2022 Apr;480(4):855-871. doi: 10.1007/s00428-021-03232-0. Epub 2021 Nov 15. Virchows Arch. 2022. PMID: 34782936 Free PMC article.

2

Best practices for the extraction of genomic DNA from formalin-fixed paraffin-embedded tumor tissue for cancer genomic profiling tests.

Inoue H, Tomida S, Horiguchi S, Kato H, Matsuoka H, Sanehira E, Matsuoka M, Yanai H, Hirasawa A, Toyooka S. Inoue H, et al. Among authors: hirasawa a. Pathol Int. 2021 May;71(5):360-364. doi: 10.1111/pin.13086. Epub 2021 Mar 3. Pathol Int. 2021. PMID: 33657250 Free article.

3

Amplification of GNAS may be an independent, qualitative, and reproducible biomarker to predict progression-free survival in epithelial ovarian cancer.

Tominaga E, Tsuda H, Arao T, Nishimura S, Takano M, Kataoka F, Nomura H, Hirasawa A, Aoki D, Nishio K. Tominaga E, et al. Among authors: hirasawa a. Gynecol Oncol. 2010 Aug 1;118(2):160-6. doi: 10.1016/j.ygyno.2010.03.010. Epub 2010 May 26. Gynecol Oncol. 2010. PMID: 20537689

4

UGT1A1 polymorphism as a prognostic indicator of stage I ovarian clear cell carcinoma patients treated with irinotecan.

Yoshihama T, Hirasawa A, Nomura H, Akahane T, Nanki Y, Yamagami W, Kataoka F, Tominaga E, Susumu N, Mushiroda T, Aoki D. Yoshihama T, et al. Among authors: hirasawa a. Jpn J Clin Oncol. 2017 Feb 4;47(2):170-174. doi: 10.1093/jjco/hyw163. Jpn J Clin Oncol. 2017. PMID: 28173214

5

Patient-derived ovarian cancer organoids capture the genomic profiles of primary tumours applicable for drug sensitivity and resistance testing.

Nanki Y, Chiyoda T, Hirasawa A, Ookubo A, Itoh M, Ueno M, Akahane T, Kameyama K, Yamagami W, Kataoka F, Aoki D. Nanki Y, et al. Among authors: hirasawa a. Sci Rep. 2020 Jul 28;10(1):12581. doi: 10.1038/s41598-020-69488-9. Sci Rep. 2020. PMID: 32724113 Free PMC article.

6

Prospective feasibility study of neoadjuvant dose-dense paclitaxel plus carboplatin with bevacizumab therapy followed by interval debulking surgery for advanced ovarian, fallopian tube, and primary peritoneal cancer patients.

Iwasa-Inoue N, Nomura H, Kataoka F, Chiyoda T, Yoshihama T, Nanki Y, Sakai K, Kobayashi Y, Yamagami W, Morisada T, Hirasawa A, Aoki D. Iwasa-Inoue N, et al. Among authors: hirasawa a. Int J Clin Oncol. 2022 Feb;27(2):441-447. doi: 10.1007/s10147-021-02050-3. Epub 2021 Oct 14. Int J Clin Oncol. 2022. PMID: 34648082

7

TP53 variants in p53 signatures and the clonality of STICs in RRSO samples.

Akahane T, Masuda K, Hirasawa A, Kobayashi Y, Ueki A, Kawaida M, Misu K, Nakamura K, Nagai S, Chiyoda T, Yamagami W, Hayashi S, Kataoka F, Banno K, Sugano K, Okita H, Kosaki K, Nishihara H, Aoki D. Akahane T, et al. Among authors: hirasawa a. J Gynecol Oncol. 2022 Jul;33(4):e50. doi: 10.3802/jgo.2022.33.e50. Epub 2022 Mar 21. J Gynecol Oncol. 2022. PMID: 35557033 Free PMC article.

8

EGRI and FOSB gene expressions in cancer stroma are independent prognostic indicators for epithelial ovarian cancer receiving standard therapy.

Kataoka F, Tsuda H, Arao T, Nishimura S, Tanaka H, Nomura H, Chiyoda T, Hirasawa A, Akahane T, Nishio H, Nishio K, Aoki D. Kataoka F, et al. Among authors: hirasawa a. Genes Chromosomes Cancer. 2012 Mar;51(3):300-12. doi: 10.1002/gcc.21916. Epub 2011 Nov 17. Genes Chromosomes Cancer. 2012. PMID: 22095904

9

High Expression of p62 Protein Is Associated with Poor Prognosis and Aggressive Phenotypes in Endometrial Cancer.

Iwadate R, Inoue J, Tsuda H, Takano M, Furuya K, Hirasawa A, Aoki D, Inazawa J. Iwadate R, et al. Among authors: hirasawa a. Am J Pathol. 2015 Sep;185(9):2523-33. doi: 10.1016/j.ajpath.2015.05.008. Epub 2015 Jul 7. Am J Pathol. 2015. PMID: 26162509 Free article.

10

Genome-wide DNA methylation profile of early-onset endometrial cancer: its correlation with genetic aberrations and comparison with late-onset endometrial cancer.

Makabe T, Arai E, Hirano T, Ito N, Fukamachi Y, Takahashi Y, Hirasawa A, Yamagami W, Susumu N, Aoki D, Kanai Y. Makabe T, et al. Among authors: hirasawa a. Carcinogenesis. 2019 Jul 4;40(5):611-623. doi: 10.1093/carcin/bgz046. Carcinogenesis. 2019. PMID: 30850842 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

385 results

Search Page